ABMD 33.55 Abiomed $ABMD Hit a 52 week high of 34.
Post# of 144503
Posted On: 11/18/2014 10:07:52 AM
ABMD 33.55 Abiomed $ABMD Hit a 52 week high of 34.04 Closing the day 09:44 at 33.55 -0.21 -0.62% With a day low of 33.55 and a total volume of 12,883.
ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/
ABMD Abiomed Recent Headline News
ABIOMED Earnings In Retrospect: Up 6.1% in the Last 18 Days (ABMD)
Comtex SmarTrend(R) - Mon Nov 17, 12:42PM CST
When ABIOMED (NASDAQ:ABMD) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $50.1 million. ABIOMED actually reported earnings of $0.09 per share on sales of $51.9 million, beating EPS estimates by $0.07 and beating revenue estimates by $1.8 million. Shares of ABIOMED have climbed from $31.35 to $33.25, representing a gain of 6.1% since the company reported earnings 18 days ago.
ABMD: 33.67 (-0.09)
Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 7:18AM CST
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November 20, 2014 at 10:40 a.m. GMT. The conference will be held at The Waldorf Hilton London in London, UK.
ABMD: 33.67 (-0.09)
Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), VAR: 88.34 (+0.73), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
ABIOMED (ABMD) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:33AM CST
ABIOMED (ABMD) Stock: Moving Average Crossover Alert
ABMD: 33.67 (-0.09)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), EW: 127.48 (+1.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)
Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), GMED: 22.95 (+0.52), ANGO: 16.82 (-0.03)
ABIOMED Shares Up 34.3% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 12, 9:15AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 2 weeks, ABIOMED has returned 34.28% as of today's recent price of $33.13.
ABMD: 33.67 (-0.09)
Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MTD: 291.48 (+2.51)
Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.67 (-0.09), ROKA: 3.82 (+0.07), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 33.67 (-0.09)
Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.67 (-0.09), VOLC: 11.30 (+0.22), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.92 (+1.12), ABMD: 33.67 (-0.09), JNJ: 108.78 (+0.48), AMGN: 159.61 (+0.47), EXAS: 23.13 (+0.17), ARAY: 6.96 (+0.14), HOLX: 26.52 (+0.15), PBYI: 216.00 (+4.45)
Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST
ABMD: 33.67 (-0.09)
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), ANGO: 16.82 (-0.03), HOLX: 26.52 (+0.15)
Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.67 (-0.09), CYNO: 28.10 (+0.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)
Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 33.67 (-0.09)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), FMI: 25.48 (+0.28), ANGO: 16.82 (-0.03)
Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MR: 31.16 (-0.06)
Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), BEAT: 8.18 (+0.04), ANGO: 16.82 (-0.03)
ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/
ABMD Abiomed Recent Headline News
ABIOMED Earnings In Retrospect: Up 6.1% in the Last 18 Days (ABMD)
Comtex SmarTrend(R) - Mon Nov 17, 12:42PM CST
When ABIOMED (NASDAQ:ABMD) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $50.1 million. ABIOMED actually reported earnings of $0.09 per share on sales of $51.9 million, beating EPS estimates by $0.07 and beating revenue estimates by $1.8 million. Shares of ABIOMED have climbed from $31.35 to $33.25, representing a gain of 6.1% since the company reported earnings 18 days ago.
ABMD: 33.67 (-0.09)
Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 7:18AM CST
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November 20, 2014 at 10:40 a.m. GMT. The conference will be held at The Waldorf Hilton London in London, UK.
ABMD: 33.67 (-0.09)
Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), VAR: 88.34 (+0.73), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
ABIOMED (ABMD) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:33AM CST
ABIOMED (ABMD) Stock: Moving Average Crossover Alert
ABMD: 33.67 (-0.09)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), EW: 127.48 (+1.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)
Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), GMED: 22.95 (+0.52), ANGO: 16.82 (-0.03)
ABIOMED Shares Up 34.3% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 12, 9:15AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 2 weeks, ABIOMED has returned 34.28% as of today's recent price of $33.13.
ABMD: 33.67 (-0.09)
Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MTD: 291.48 (+2.51)
Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.67 (-0.09), ROKA: 3.82 (+0.07), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 33.67 (-0.09)
Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.67 (-0.09), VOLC: 11.30 (+0.22), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.92 (+1.12), ABMD: 33.67 (-0.09), JNJ: 108.78 (+0.48), AMGN: 159.61 (+0.47), EXAS: 23.13 (+0.17), ARAY: 6.96 (+0.14), HOLX: 26.52 (+0.15), PBYI: 216.00 (+4.45)
Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST
ABMD: 33.67 (-0.09)
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), ANGO: 16.82 (-0.03), HOLX: 26.52 (+0.15)
Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.67 (-0.09), CYNO: 28.10 (+0.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)
Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 33.67 (-0.09)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), FMI: 25.48 (+0.28), ANGO: 16.82 (-0.03)
Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MR: 31.16 (-0.06)
Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), BEAT: 8.18 (+0.04), ANGO: 16.82 (-0.03)
(0)
(0)Scroll down for more posts ▼